Xbrane Biopharma AB (publ) (XBRANE.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 17.40 (+40.32%) as of
Key statistics
- Market cap
- 358.53M
- Forward P/E
- 870.00
- EPS (TTM)
- -3.73
- Dividend yield
- 0.00%
- 52-week range
- 5.42 – 20.00
- Beta
- 0.77
- Revenue (TTM)
- 83.3M
- Profit margin
- -90.04%
- Analyst target
- SEK 15.00
- Volume
- 1.46M
About Xbrane Biopharma AB (publ)
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Solna, Sweden
- Employees
- 29
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.